Mersana Earnings Reports

The company saw a year-over-year decline in collaboration revenue and a wider net loss. However, it progressed enrollment in its clinical trial for Emi-Le and maintains a solid cash position to support operations into mid-2026.

Mersana Therapeutics reported an increase in collaboration revenue to $16.4 million, a reduction in net loss to $14.1 million, and continued progress in clinical trials. The company remains focused on advancing its pipeline and maintains sufficient capital resources into 2026.

Mersana Therapeutics reported its Q3 2024 financial results, highlighting the advancement of XMT-1660 and XMT-2056 clinical trials, progress in collaborations, and maintenance of a strong balance sheet. The company is preparing to present initial XMT-1660 clinical data and initiate the expansion portion of its trial.

Mersana Therapeutics reported financial results for the second quarter ended June 30, 2024. The company is advancing dose escalation in Phase 1 clinical trials of XMT-1660 and XMT-2056 and has made progress in its collaborations. Mersana earned an $8 million development milestone under the Johnson & Johnson collaboration.

Mersana Therapeutics continues to advance its Phase 1 clinical trial of XMT-1660 and resumed patient recruitment in its Phase 1 clinical trial of XMT-2056. The company plans to share initial dose escalation and backfill cohort data and initiate the expansion portion of the trial in the second half of 2024.

Mersana Therapeutics reported the advancement of its clinical trials for XMT-1660 and XMT-2056, progress in collaborations with Johnson & Johnson and Merck KGaA, and provided an update on its financial results for the fourth quarter and full year ended December 31, 2023.

Mersana Therapeutics is advancing XMT-1660 in Phase 1 dose escalation and preparing to resume enrollment in the Phase 1 clinical trial of XMT-2056. The company reported top-line data from UPLIFT, its Phase 2 clinical trial of upifitamab rilsodotin (UpRi), that showed the trial did not meet its primary endpoint.

Mersana Therapeutics announced its Q2 2023 financial results, highlighting the advancement of XMT-1660 and XMT-2056, along with progress in its Dolasynthen and Immunosynthen platforms. The company is focused on developing new product candidates and business development opportunities. Mersana is working to address the clinical hold on its Phase 1 clinical trial of XMT-2056.

Mersana Therapeutics reported its first quarter 2023 financial results, highlighting the anticipation of topline data for UPLIFT and a comprehensive development plan for UpRi. The company is focused on ADC innovation and advancing its pipeline, supported by a solid financial position.

Mersana Therapeutics reported their Q4 and Full Year 2022 financial results, highlighting advancements in their lead product candidate UpRi, diversification of their clinical pipeline, new collaborations, and a strengthened financial position.

Mersana Therapeutics reported its Q3 2022 financial results, highlighting advancements in UpRi, expansion of the clinical pipeline, and strengthened balance sheet through partnerships.

Mersana Therapeutics reported progress in 2022, including building UpRi as a potential foundational medicine in ovarian cancer, achieving key regulatory goals with XMT-1660 and XMT-2056, and entering into two new strategic partnerships with Janssen and GSK.

Mersana Therapeutics reported its Q1 2022 financial results and provided a business update, highlighting the potential of UpRi to transform ovarian cancer treatment and the advancement of XMT-1660 and XMT-2056 into clinical trials.

Mersana Therapeutics reported its Q4 2021 financial results, highlighting progress in its UpRi development plan, advancements in its ADC pipeline, and a strengthened financial position through strategic partnerships and financing activities.

Mersana Therapeutics reported cash and cash equivalents of $191.7 million as of September 30, 2021. Net cash used in operating activities in the third quarter of 2021 was $36.1 million. The Company expects that its available funds will be sufficient to support its operating plan commitments into the first half of 2023.

Mersana Therapeutics reported cash and cash equivalents of $227.4 million as of June 30, 2021. Net cash used in operating activities in the second quarter of 2021 was $34.5 million. The Company expects that its available funds will be sufficient to support its operating plan commitments for approximately two years.

Mersana Therapeutics announced the initiation of UPLIFT, a single-arm registrational strategy for evaluating UpRi in platinum-resistant ovarian cancer. The company ended the first quarter of 2021 with $228.4 million in cash and cash equivalents.

Mersana Therapeutics reported its Q4 and full year 2020 financial results, highlighting the progress of UpRi in ovarian cancer and advancements in its ADC pipeline. The company ended the year with $255.1 million in cash and expects these funds to support its operating plan for approximately the next two years.

Mersana Therapeutics reported cash and cash equivalents of $270.9 million as of September 30, 2020. Net cash used in operating activities in the third quarter of 2020 was $20.2 million. The company expects that its cash and cash equivalents will enable it to fund its current operating plan commitments for more than two years.

Mersana Therapeutics reported having $291.4 million in cash, cash equivalents and marketable securities as of June 30, 2020. Net cash used in operating activities in the second quarter of 2020 was $15.9 million.

Mersana Therapeutics reported its Q1 2020 financial results, highlighting the progress of XMT-1536 and the company's response to the COVID-19 pandemic. The company's cash, cash equivalents, and marketable securities totaled $78.4 million as of March 31, 2020, and they raised $65.0 million in gross proceeds through the sale of common stock.

Mersana Therapeutics reported its Q4 and full year 2019 financial results, highlighting the upcoming presentation of XMT-1536 data at the SGO 2020 Annual Meeting and planned data disclosures throughout the year. The company's cash, cash equivalents, and marketable securities were $99.8 million as of December 31, 2019.